We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Report: FDA Likely to Require Trials to Establish Interchangeable Biosimilars
Report: FDA Likely to Require Trials to Establish Interchangeable Biosimilars
Biosimilar developers can expect the FDA to demand costly clinical trials to verify that a biosimilar is effectively identical with a reference product.